Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyFluATG Conditioning for Allogeneic HCT in Lower Risk MDS
NCT06098326Phase 2Active, not recruiting
- Sponsor
- Asan Medical Center
- Start
- Mar 2018
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, fludarabine and antithymocyte globulin in myelodysplastic syndrome (MDS), sponsored by Asan Medical Center. Primary endpoints: Engraftment at 8 years and Non-Relapse Mortality at 8 years. Started Mar 2018; status: active, not recruiting.
02
Drugs
cyclophosphamidefludarabineantithymocyte globulin
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06098326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098326.